<DOC>
	<DOCNO>NCT00003137</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient advance cancer stomach .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Advanced Cancer Stomach</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate , survival , toxicity previously untreated patient locally advance metastatic gastric cancer treat irinotecan ( CPT-11 ) . OUTLINE : This nonrandomized study . Patients receive irinotecan ( CPT-11 ) IV 90 minute every 3 week . Dosage modification make base toxicity . Retreatment may delay another 3 week ( total 6 week ) allow recovery toxic effect . Patient take study recover toxic effect , unless cause document unrelated CPT-11 . Patients stable disease partial response continue treatment disease progression intolerable toxicity . Patients complete response continue treatment another 2 course observe . Patients follow every 3 month 3 year disease progression .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced adenocarcinoma stomach gastroesophageal junction beyond hope surgical cure consider candidate potentially curative chemotherapy/radiation therapy Measurable evaluable disease Tumor must accessible biopsy No known central nervous system metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 150,000/mm3 Hemoglobin least 9.0 mg/dL ( transfusion allow ) Hepatic : Bilirubin great upper limit normal ( ULN ) , regardless liver involvement secondary tumor AST great 3 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina No uncontrolled high blood pressure No active congestive heart failure No myocardial infarction last 6 month No serious uncontrolled cardiac arrhythmia No New York Heart Association Class III IV heart disease Pulmonary : No interstitial pneumonia extensive symptomatic interstitial fibrosis lung No pleural effusion ascites , cause respiratory compromise ( least Grade 2 dyspnea ) Other : No active uncontrolled infection No prior malignancy , except adequately treat basal cell squamous cell skin cancer , adequately treat noninvasive carcinoma , cancer patient disease free least 5 year Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy gastric gastroesophageal junction cancer No prior irinotecan ( CPT11 ) camptothecin Endocrine therapy : Not specify Radiotherapy : No prior abdominal pelvic radiotherapy No prior radiotherapy great 25 % bone marrow No prior radiotherapy measurable evaluable indicator lesion At least 4 week since major radiotherapy ( chest radiotherapy ) Surgery : At least 3 week since major surgery recover At least 2 week since minor surgery recover Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>intestinal adenocarcinoma stomach</keyword>
	<keyword>diffuse adenocarcinoma stomach</keyword>
	<keyword>mixed adenocarcinoma stomach</keyword>
</DOC>